Renal Elimination of the Hypoxic Cell Radiosensitizer Misonidazole in Wistar Rats: Influence of Some Drugs on Its Excretion

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 1985 Jul 1

PMID 4085520

Citations 1

Authors

G Akel

P Canal

G Soula

Affiliations

Soon will be listed here.

Abstract

The hypoxic cell radiosensitizing drug, misonidazole (Miso) (Ro 07-0582) and its demethylated metabolite were administered to Wistar rats at different dose levels to examine their renal elimination. The data were consistent with a model in which Miso is eliminated mainly after biotransformation into desmethylmisonidazole (Demiso) which is eliminated according to its renal clearance. The study of Miso renal elimination process shows a tubular reabsorption. So we analyzed the interaction of various drugs on urinary 24 hours elimination of this radiosensitizer. Following results were observed: Furosemide and acetazolamide do not change the rate of renal elimination of the drug; Soludactone increases the elimination level of unmetabolized Miso (p less than 0.01); Under probenecid treatment, the elimination of Miso and its O-demethylated derivative are increased; On the other hand, after a pretreatment with phenobarbital, the urinary level of desmethylmisonidazole is strongly increased (p less than 0.001).

Citing Articles

Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P Eur J Nucl Med Mol Imaging. 2007; 34(9):1348-54.

PMID: 17334763 DOI: 10.1007/s00259-007-0376-7.

References

Dische S, Saunders M, Flockhart I, Lee M, Anderson P . Misonidazole-a drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys. 1979; 5(6):851-60. DOI: 10.1016/0360-3016(79)90070-1. View

Ross D, GALE G . Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep. 1979; 63(5):781-7. View

Workman P . Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer. 1979; 40(3):335-53. PMC: 2010042. DOI: 10.1038/bjc.1979.187. View

McManus M, Monks A, Collins J, White R, Strong J . Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver. J Pharmacol Exp Ther. 1981; 219(3):669-74. View

Marshall W, McLean A . The effect of oral phenobarbitone on hepatic microsomal cytochrome P-450 and demethylation activity in rats fed normal and low protein diets. Biochem Pharmacol. 1969; 18(1):153-7. DOI: 10.1016/0006-2952(69)90020-3. View

White R, Workman P, Freedman L, OWEN L, Bleehen N . The pharmacokinetics of misonidazole in the dog. Eur J Cancer (1965). 1979; 15(10):1233-42. DOI: 10.1016/0014-2964(79)90249-4. View

Gangji D, Poplack D, Schwade J, WOOD J, Strong J . Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration. Eur J Cancer (1965). 1981; 17(1):29-34. DOI: 10.1016/0014-2964(81)90208-5. View

Wasserman T, Phillips T, Van Raalte G, Urtasun R, Partington J, Koziol D . The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol. 1980; 53(626):172-3. DOI: 10.1259/0007-1285-53-626-172. View

Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R . Kinetics and renal handling of cefonicid. Clin Pharmacol Ther. 1981; 30(5):587-93. DOI: 10.1038/clpt.1981.208. View

10.

Workman P . Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol. 1980; 5(1):27-37. DOI: 10.1007/BF00578559. View

11.

Millar B, Jinks S . The effect of dexamethasone on the radiation survival response and misonidazole-induced hypoxic-cell cytotoxicity in Chinese hamster cells V-79-753B in vitro. Br J Radiol. 1981; 54(642):505-11. DOI: 10.1259/0007-1285-54-642-505. View

12.

Workman P, Little C, Marten T, DALE A, Ruane R, Flockhart I . Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978; 145(3):507-12. DOI: 10.1016/s0378-4347(00)81386-9. View

13.

Dische S, Saunders M, Lee M, Adams G, Flockhart I . Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977; 35(5):567-79. PMC: 2025511. DOI: 10.1038/bjc.1977.90. View

14.

Pirttiaho H, Sotaniemi E, Ahokas J, Pitkanen U . Liver size and indices of drug metabolism in epileptics. Br J Clin Pharmacol. 1978; 6(3):273-8. PMC: 1429461. DOI: 10.1111/j.1365-2125.1978.tb04597.x. View

15.

Millar B, Jinks S, Powles T . Flurbiprofen, a non-steroid anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro. Br J Cancer. 1981; 44(5):733-40. PMC: 2010854. DOI: 10.1038/bjc.1981.260. View

16.

Ward J, Grabin M, LeRoy A, Young D . Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats. Cancer Treat Rep. 1977; 61(3):375-9. View

17.

Runkel R, Mroszczak E, Chaplin M, SEVELIUS H, Segre E . Naproxen-probenecid interaction. Clin Pharmacol Ther. 1978; 24(6):706-13. DOI: 10.1002/cpt1978246706. View